Key US Advisory Committee to Decide on Altering Baby Hepatitis B Vaccine Recommendation

Following a delay and a particularly heated meeting, a federal vaccine advisory panel was set to cast ballots on Friday regarding a potential change to the long-held guideline that all newborns be inoculated against hepatitis B.

Intense Discussion and a Delayed Ballot

The initial day of the meeting on Thursday was defined by fiery discussion over limiting availability to the hepatitis B vaccine for newborns and a choice to defer the vote by a day to give members more time to review the wording. The panel, which counsels the Centers for Disease Control and Prevention on vaccine use, had previously delayed on two occasions.

“Is there any concrete proof of damage of giving this vaccination before 30 days? Or is this theory?” inquired one adviser.

In answer, another participant stated, “There is scant proof about the prolonged hazard.”

Present Protocol and Likely Ramifications

The shot is currently suggested for every newborn within 24 hours of being born to prevent infection of hepatitis B, which can lead to major damage to the liver. It has been administered to more than a billion persons for in excess of thirty years.

The Atlanta conference provided no fresh data of harms caused by the vaccine. Specialists note any modification to the current hepatitis B immunization timeline could have significant and far-reaching repercussions for infant and child health in the United States.

Committee Makeup and New Appointments

The expert committee can only make recommendations to the director of the CDC. The panel's membership has experienced alterations recently, with the announcement that the group's former head would depart for an official role and be succeeded by a cardiac doctor who has been questioning of other vaccines.

The panel includes a number of immunization doubters who support a aim to revamp – and perhaps, in some cases, abolish – longstanding immunization guidelines.